Adjuvant Effect of Orally Applied Preparations Containing Non-Digestible Polysaccharides on Influenza Vaccination in Healthy Seniors: A Double-Blind, Randomised, Controlled Pilot Trial

Nutrients

R. Paul Ross¹  Yala Stevens²  Monique van Erp²  Ekaterina Papazova³  Christiane Laue³  Juergen Schrezenmeir³  Edlyn Soeth³  Angelika Pannenbeckers³  Ruwen Böhm³  Jerry M. Wells⁴  Ellen Stolte⁴  Sylvie van der Werf⁵  Simon Ballance⁶  Svein H. Knutsen⁶  Sam Possemiers⁷  Iris Pinheiro⁷  Paul M. Ryan⁸  Catherine Stanton⁸  Sophie Le Gall⁹  Xavier Falourd⁹  Jurriaan J. Mes^1,10 

[1] APC Microbiome Ireland, University College Cork, T12 YT20 Cork, Ireland;BioActor, Brightlands Health Campus, 6229 GS Maastricht, The Netherlands;Clinical Research Center Kiel, Kiel Center of Innovation and Technology, 24118 Kiel, Germany;Host-Microbe Interactomics, Wageningen University & Research, 6708 WD Wageningen, The Netherlands;Institut Pasteur, 75015 Paris, France;Nofima, Norwegian Institute of Food Fisheries & Aquaculture Research , 1433 Ås, Norway;Prodigest, Technologiepark-Zwijnaarde, 9052 Ghent, Belgium;Teagasc, Food Research Centre, Moorepark, Fermoy, Co., P61 C996 Cork, Ireland;UR1268 BIA, INRA, 44316 Nantes, France;Wageningen Food and Biobased Research, Wageningen University & Research, 6708 WG Wageningen, The Netherlands;

关键词: adjuvant;    immunity;    non-digestible polysaccharide;    prebiotics;    arabinoxylan;    β-glucan;   

DOI  :  10.3390/nu13082683

来源: DOAJ

【 摘 要 】

Senior individuals can suffer from immunosenescence and novel strategies to bolster the immune response could contribute to healthy ageing. In this double-blind, randomised, controlled pilot trial, we investigated the ability of non-digestible polysaccharide (NPS) preparations to enhance the immune response in a human vaccination model. In total, 239 subjects (aged 50–79 years) were randomised to consume one of five different NPS (yeast β-glucan (YBG), shiitake β-glucan (SBG), oat β-glucan (OBG), arabinoxylan (AX), bacterial exopolysaccharide (EPS)) or control (CTRL) product daily for five weeks. After two weeks of intervention, subjects were vaccinated with seasonal influenza vaccine. The post-vaccination increases in haemagglutination inhibition antibody titres and seroprotection rate against the influenza strains were non-significantly enhanced in the NPS intervention groups compared to CTRL. Specifically, a trend towards a higher mean log₂ fold increase was observed in the AX group (uncorrected p = 0.074) combined with a trend for an increased seroprotection rate, AX group (48.7%) compared to CTRL (25.6%) (uncorrected p = 0.057), for the influenza A H1N1 strain. Subjects consuming AX also had a reduced incidence of common colds compared to CTRL (1 vs. 8; p = 0.029 in Fisher exact test). No adverse effects of NPS consumption were reported. The findings of this pilot study warrant further research to study AX as an oral adjuvant to support vaccine efficacy.

【 授权许可】

Unknown